ClinicaliQ Trial Snapshot
- REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia — Recruiting • Cardiology / Cardiovascular • NCT07270575.
- What is being tested: Esprit BTK™ Everolimus Eluting Resorbable Scaffolds are being evaluated in a European multicentre study of 400 patients to assess their real-world effectiveness in treating infrapopliteal (below-knee) artery disease in critical limb-threatening ischaemia.
- Patient eligibility overview: The trial focuses on patients with critical limb-threatening ischaemia who have heavily diseased or calcified infrapopliteal arteries, representing a high-risk population with limited treatment options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
RESCUE is a Europe-wide study that will follow 400 people with critical limb-threatening ischemia (CLTI). It aims to see how well Esprit BTK™ Everolimus Eluting Resorbable Scaffolds work in real-life medical settings. The study focuses on people who have heavily calcified arteries in the infrapopliteal areas of the leg. These drug-eluting resorbable scaffolds release a medication that helps prevent the inner wall of the blood vessel from thickening after injury or surgery. This can reduce the chance of the artery becoming blocked again (a problem called restenosis), while also giving…
Eligibility Snapshot
- : 1. Rutherford classification category ≥4; 2. Treatment of infrapopliteal lesions with the Esprit BTK everolimus eluting resorbable scaffold system following adequate vessel preparation; 3. Calcification of target lesions must be visible on fluoroscopy or CT-angiography; 4. Patients competent and willing to provide informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.